Parkinson disease (PD) is associated with increased sedentary time and reduced cardiorespiratory fitness, making exercise a core element of symptom management and health promotion. While aerobic exercise can improve maximal oxygen consumption (VO2max), individuals with PD show substantial heterogeneity in fitness response. The role of sedentary behavior as a modifier of exercise response, and whether this varies by exercise intensity, has not been clearly established in PD.
The Study in Parkinson Disease of Exercise (SPARX) Phase 2 randomized clinical trial provided an opportunity to examine whether average sedentary time during the intervention period interacted with randomized assignment to moderate-intensity or high-intensity treadmill exercise versus usual care to influence 6-month change in VO2max.
This secondary analysis used data from 128 participants with de novo PD enrolled in the SPARX Phase 2 randomized clinical trial. Participants were randomized to one of three arms for 6 months: high-intensity treadmill exercise, moderate-intensity treadmill exercise, or usual care.
The primary analytic approach assessed interactions between randomized group assignment and the post-randomization 6-month average sedentary time. Linear regression models structured as Analysis of Covariance (ANCOVA) with interaction terms were used to estimate associations with 6-month change in VO2max. Sensitivity analyses included a complete-case analysis restricted to participants with available data.
Key outcomes reported are regression coefficients (β) for the interaction terms comparing each exercise intensity group with usual care, together with 95% confidence intervals and p-values. The trial was registered under NCT01506479 and ethical approvals were obtained from institutional review boards at all participating sites.
For the comparison of the moderate-intensity exercise group versus usual care, the primary interaction estimate between exercise intensity and 6-month average sedentary time on VO2max change did not reach conventional statistical significance (β = -1.78, 95% CI -3.76 to 0.20, p = 0.08). This estimate indicates a trend whereby greater sedentary time was associated with smaller improvements in VO2max in the moderate-intensity arm compared with usual care, but the finding was not statistically definitive in the primary analysis.
A complete-case sensitivity analysis limited to participants with complete data showed a statistically significant interaction for the moderate-intensity group: each 10% increase in 6-month average sedentary time was associated with a 2.51 mL/kg/min decrease in VO2max change compared with usual care (β = -2.51, 95% CI -4.53 to -0.48, p = 0.02). This sensitivity result suggests that higher sedentary behavior during the intervention may materially attenuate VO2max gains in those assigned to moderate-intensity aerobic training.
In contrast, there was no significant interaction detected for the high-intensity exercise group versus usual care (β = -1.46, 95% CI -4.74 to 1.83, p = 0.38). The authors report that sensitivity analyses for the high-intensity comparison produced similar null findings.
The SPARX Phase 2 secondary analysis produces hypothesis-generating evidence that sedentary time may modify the cardiorespiratory fitness response to 6 months of moderate-intensity aerobic exercise in individuals with de novo PD. The primary interaction did not meet statistical significance in the overall analysis, but a complete-case sensitivity analysis suggested a clinically relevant attenuation of VO2max improvement with greater sedentary time in the moderate-intensity arm.
No evidence from this analysis supports a modifying effect of sedentary time on VO2max response to high-intensity exercise compared with usual care.
Authors emphasize that these findings are preliminary: they were derived from a secondary analysis and should not be used to guide clinical practice without confirmation. The results indicate that future, adequately powered randomized controlled trials should prospectively evaluate sedentary behavior as a potential effect modifier when prescribing exercise intensity for people with PD.
This study reports a secondary analysis of data from the SPARX Phase 2 randomized clinical trial (ClinicalTrials.gov identifier NCT01506479). Ethical approval for the SPARX trial was obtained from the institutional review boards or ethics committees at all participating sites, including the University of Colorado, University of Illinois at Chicago, Northwestern University, Rush University Medical Center, and the University of Pittsburgh. The authors confirm informed consent procedures and necessary approvals were completed for the original trial.
The original SPARX dataset was shared with the National Institute of Neurological Disorders and Stroke (NINDS) in May 2017; data requests should be directed to NINDS. Funding sources listed for the work include grants and institutional support from the National Institute of Neurologic Disease and Stroke (NINDS R01 NS074343), Clinical and Translational Science Awards at participating universities, the Nutrition and Obesity Research Center, NIH career development support, and the Parkinson’s Disease Foundation. The authors declared no competing interests.
These results arise from a secondary, exploratory analysis and should be interpreted cautiously. The primary interaction for the moderate-intensity group did not reach statistical significance, and the significant finding emerged in a complete-case sensitivity analysis; both the potential for chance findings and missing-data impacts must be considered. The study authors label the results as hypothesis-generating rather than confirmatory.
Implications include the possibility that reducing sedentary time could be important to realize the full cardiorespiratory benefits of moderate-intensity aerobic exercise in PD. Conversely, high-intensity exercise responses appeared less modified by sedentary behavior in this analysis. The authors recommend adequately powered randomized trials that prospectively measure and possibly intervene on sedentary behavior to determine whether exercise prescriptions for people with PD should explicitly account for sedentary time.